---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-002961"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2022-04-27T23:59:59+00:00"
generated_at: "2026-06-26T04:05:25.121728+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences in-licenses DNase oncology platform from CLS Therapeutics for $500K cash + 875K shares + milestones

## Summary
- Upfront payment: $500K cash + 875,000 common shares (250,000 issued to OPKO per third-party obligation).
- Milestone payments up to $13M per program in cash plus up to 950,000 additional shares for regulatory milestones.
- Licensed platform includes systemic DNase (co-admin with chemo/IO) and DNase-armored CAR T therapies.
- Xenetic plans Phase 1 study of lead asset in locally advanced or metastatic solid tumors.
- Tiered royalties on net sales (mid-single to low-double digits); sublicense revenue share in mid-teens to low-double digits.

## SEC filing metadata
- accession: 0001683168-22-002961
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2022-04-27T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316822002961/0001683168-22-002961-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316822002961/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-002961
- JSON: https://secwatch.observer/filing/0001683168-22-002961.json
- Plain text: https://secwatch.observer/filing/0001683168-22-002961.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.